Molecular Pain, 2019 Background Memantine is one of the important clinical medications in treating moderate to severe Alzheimer disease. The effect of memantine on preventing or treating punctate allodynia has been thoroughly studied but not on the induction of dynamic ...
Yangyang Chen +5 more
doaj +1 more source
Possible Antidepressant Effects of Memantine—Systematic Review with a Case Study
Pharmaceuticals, 2021 The treatment of bipolar depression is hampered by the inadequate efficacy of antidepressants, moderate effect of mood stabilizers, and the side effects of some second-generation antipsychotics.
Marek Krzystanek +4 more
doaj +1 more source
Modulatory Effects of Memantine on Neuronal Response Properties in Rat Barrel Cortex
Basic and Clinical Neuroscience, 2021 Introduction: Memantine as N-Methyl-D-Aspartic Acid (NMDA) receptor antagonist is used in some neurological disorders. Moreover, memantine presents modulatory effects on the somatosensory information processing in healthy subjects.
Mahin Nasiri +7 more
doaj
Memantine inhibits α3β2-nAChRs-mediated nitrergic neurogenic vasodilation in porcine basilar arteries. [PDF]
PLoS ONE, 2012 Memantine, an NMDA receptor antagonist used for treatment of Alzheimer's disease (AD), is known to block the nicotinic acetylcholine receptors (nAChRs) in the central nervous system (CNS).
Reggie Hui-Chao Lee +6 more
doaj +1 more source
Calcium in the initiation, progression and as an effector of Alzheimer's disease pathology. [PDF]
, 2009 The cause(s) of sporadic Alzheimer's disease (sAD) are complex and currently poorly understood. They likely result from a combination of genetic, environmental, proteomic and lipidomic factors that crucially occur only in the aged brain.
Green, Kim N
core +1 more source
The dichotomy of memantine treatment for ischemic stroke: dose-dependent protective and detrimental effects. [PDF]
, 2014 Excitotoxicity is a major contributor to cell death during the acute phase of ischemic stroke but aggressive pharmacological targeting of excitotoxicity has failed clinically.
Fern, R +3 more
core +4 more sources
A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders
Clinical Pharmacology &Therapeutics, EarlyView.Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel +3 more
wiley +1 more source
Frontiers in Pharmacology, 2019 Alpha7 nicotinic acetylcholine receptors (nAChRs) play an important role in learning and memory and are promising targets for pharmacological cognitive enhancement.
Zsolt Kristóf Bali +15 more
doaj +1 more source
Resposta à Carta ao Editor Relativa ao Trabalho “Prescrição Inapropriada em Idosos numa Enfermaria de Medicina Interna” Mariana Alves, Marco Ribeiro Narciso, Teresa Fonseca, João Gorjão Clara” [Acta Med Port.2019;32:249-249] [PDF]
, 2019 info:eu-repo/semantics ...
Urzal, JI
core +1 more source
Precision therapies for genetic epilepsies in 2025: Promises and pitfalls
Epilepsia Open, EarlyView.Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang +3 more
wiley +1 more source